Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease-Reference-Cited by-同舟云学术

Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease

Published:2017-12 Issue: Volume:37 Page:65-71
ISSN:1471-4892
Container-title:Current Opinion in Pharmacology
language:en
Short-container-title:Current Opinion in Pharmacology

Author:

Park Sang Hyoung,Aniwan Satimai,Loftus Edward V

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference52 articles.

1. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970–2004);Peyrin-Biroulet;Am J Gastroenterol,2012

2. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis;Samuel;Inflamm Bowel Dis,2013

3. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort;Thia;Gastroenterology,2010

4. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice;Levesque;Gastroenterology,2015

5. Ustekinumab as induction and maintenance therapy for Crohn's disease;Feagan;N Engl J Med,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of NADPH Oxidase (NOX) 2 Mitigates Colitis in Mice with Impaired Macrophage AMPK Function;Biomedicines;2023-05-14

2. A potent HNF4α agonist reveals that HNF4α controls genes important in inflammatory bowel disease and Paneth cells;PLOS ONE;2022-04-06

3. Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK;Inflammatory Bowel Diseases;2020-11-30

4. Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions;Crohn's & Colitis 360;2020-04-01

5. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease;Crohn's & Colitis 360;2019-10-01